TAO Synergies logo
TAO Synergies
TAOX | NASDAQ
Chart Builder DCF Calculator
$1.86
-$0.24 (-11.43%)
At close: Nov 16, 2026, 4:00 PM ET
$1.90
+$0.04 (+2.15%)
After-hours: Nov 16, 2026, 5:23 PM ET

TAO Synergies Company Profile

Company profile explained

Company Profile

TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.

Key Executives

Name Position
Robert Weinstein Chief Financial Officer, Executive Vice President, Treasurer & Secretary
Alan J. Tuchman Chief Medical Officer
Joshua N. Silverman Executive Chairman of the Board

Latest SEC Filings

Date Type Title
Oct 23, 2026 S-3/A [Amend] Filing
Oct 09, 2026 S-3/A [Amend] Filing
Aug 13, 2026 10-Q Quarterly Report
Jun 05, 2026 10-K/A [Amend] Annual Report
May 19, 2026 4 Filing
May 19, 2026 4 Filing
May 19, 2026 4 Filing
May 19, 2026 4 Filing
May 19, 2026 4 Filing
May 13, 2026 10-Q Quarterly Report
View All SEC Filings ➞
TAO Synergies
TAO Synergies logo
Country United States
IPO Date Jul 2, 2025
Industry Software - Application
Sector Technology
Employees 5
CEO Joshua N. Silverman

Contact Details

1185 Avenue of the Americas, 3rd Floor New York, New York 10036 United States

Stock Details

Ticker Symbol TAOX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001571934
CUSIP Number 87167T300
ISIN Number US87167T3005
SIC Code 6199

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.